Aerobic Exercise for Type 2 Diabetes
(EPC-DM Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Baltimore VA Medical Center

No Placebo Group

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The discovery of the role of endothelial progenitor cells (EPCs) and their involvement in the cardiovascular complications of type 2 diabetes (T2DM) would quickly have a significant impact on the millions of Americans who have T2DM. This project is designed to 1) determine the mechanisms underlying EPC dysfunction in older, sedentary adults with T2DM compared those with normal glucose metabolism and impaired glucose metabolism, and 2) determine if aerobic exercise training is an efficacious therapy for EPC dysfunction in T2DM, and whether improvement in EPC number and function translates to improved endothelial function, increased capillarization, and improved glucose metabolism in T2DM.

Research Team

Eligibility Criteria

This trial is for non-smoking adults aged 50-80 with type 2 diabetes, particularly those who are sedentary. Women must be postmenopausal for over a year. It's not suitable for individuals with kidney or liver diseases, uncontrolled high blood pressure or cholesterol levels, or a history of cancer, heart disease, or stroke.

Inclusion Criteria

You do not smoke cigarettes.

I am a woman who has been postmenopausal for more than a year.

I am between 50 and 80 years old.

Exclusion Criteria

My blood pressure or cholesterol levels are not well-managed.

I have had cancer in the past.

I have a kidney or liver disease.

See 1 more

Treatment Details

Interventions

Aerobic Exercise Training (Behavioural Intervention)

Trial OverviewThe study is testing whether aerobic exercise training can improve the function and number of endothelial progenitor cells (EPCs) in older adults with type 2 diabetes. The goal is to see if this leads to better blood vessel health and glucose metabolism.

Participant Groups

3Treatment groups

Experimental Treatment

Active Control

Group I: T2DMExperimental Treatment1 Intervention

Type 2 Diabetes Mellitus

Group II: IGTExperimental Treatment1 Intervention

Impaired Glucose Tolerance

Group III: NGTActive Control1 Intervention

Normal Glucose Tolerance